Welcome to our dedicated page for Emergent Biosolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Emergent BioSolutions Inc. (NYSE: EBS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New York Stock Exchange‑listed pharmaceutical preparation manufacturing company, Emergent submits annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K that describe its operations, financial condition and material events.
In its recent Form 8‑K filings, Emergent has reported topics such as quarterly financial and operating results, voluntary prepayment under a term loan facility, contract modifications and options for medical countermeasures, regulatory approvals for manufacturing changes, and changes in board membership. These current reports often incorporate press releases and presentation materials by reference, giving additional detail on product revenues, segment performance and government contract activity.
Filings also confirm that Emergent’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol EBS. Disclosures identify its reportable segments, including Commercial Products and MCM Products, and describe how Services and contracts and grants revenues are presented. Other events filings outline contract modifications with agencies such as the Administration for Strategic Preparedness and Response and BARDA for products including ACAM2000®, CYFENDUS™, BioThrax® and BAT®.
On Stock Titan, investors can review these SEC documents alongside AI‑generated summaries that highlight key points from lengthy filings. Real‑time updates from EDGAR surface new 10‑K and 10‑Q reports as they are filed, while Form 8‑K items flag significant developments in financing, contracts, regulatory approvals and governance. Users can also track how Emergent describes its medical countermeasures portfolio, naloxone products and segment structure over time through its official regulatory language.
Emergent BioSolutions Inc. senior vice president of Products Business Paul Anthony Williams reported an open-market sale of Common Stock. On April 1, 2026, he sold 4,000 shares at a weighted average price of $8.44 per share. The trades occurred within a price range of $8.34 to $8.54 and were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on November 14, 2025. Following this sale, Williams directly holds 62,681 shares of Emergent BioSolutions common stock.
Emergent BioSolutions Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock as of 03/13/2026, representing 0% of the class. The filing cites an internal realignment and reliance on SEC Release No. 34-39538 that led certain Vanguard subsidiaries to report holdings separately. The form is signed on 03/26/2026 by Ashley Grim, Head of Global Fund Administration.
Emergent BioSolutions summarizes progress on its multi-year turnaround, reporting operational and balance-sheet improvements in 2025. The company says it improved cash by $100M, reduced debt by $110M, secured multiple U.S. government biodefense contracts, and expanded its naloxone franchise including exclusive rights to KLOXXADO.
The company also reports distribution of over 100 million doses of NARCAN® since 2016, FDA approval for raxibacumab drug product manufacturing at Winnipeg, a divestiture of the Baltimore‑Bayview facility for $36, and an announced investment agreement with Swiss Rockets AG. The board and governance items, annual meeting details, and investor contacts are provided.
Emergent BioSolutions Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification, executive pay and an increase to the share reserve under its stock incentive plan.
Stockholders will elect four Class II directors to terms ending in 2029, vote on ratifying Ernst & Young LLP as independent auditor for 2026, cast an advisory say-on-pay vote on 2025 compensation for named executive officers, and decide on expanding the Amended and Restated Stock Incentive Plan. The company highlights a turnaround in 2025, with total revenue of $742.9 million versus $1,043.6 million in 2024, net income of $52.6 million after a prior-year loss, and adjusted EBITDA of $205.0 million.
The proxy describes a heavily independent, skills-diverse board, detailed committee structure, and pay-for-performance compensation design emphasizing variable and equity-based pay. It also discloses major institutional holders and shows that executives and directors collectively beneficially own 6.0% of outstanding common stock as of March 6, 2026.
Emergent BioSolutions Inc. executive vice president and chief financial officer Richard S. Lindahl reported the expiration of two employee stock option awards. Stock options for 20,321 shares and 19,963 shares expired unexercised pursuant to their terms, and the footnotes state that no value was received upon expiration.
Emergent BioSolutions Inc. reported that President and CEO Joseph C. Papa received an award of employee stock options covering 252,194 shares on March 3, 2026, at an exercise price of $0.00 per share. These options vest in three equal installments beginning the day prior to each anniversary of the grant date.
On March 5, 2026, 37,055 shares of common stock were withheld and disposed of to cover taxes tied to the vesting and settlement of performance stock units at a price of $8.44 per share, leaving Papa with 305,445 common shares directly owned.
FOWLER JOHN D JR reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. director John D. Fowler Jr reported an equity award of 5,006 shares of common stock in the form of restricted stock units. The units were granted at a reference value of $8.99 per share and were issued under the company’s Stock Incentive Plan.
These 5,006 restricted stock units vest in three annual installments, beginning on the day prior to the anniversary of the grant date, assuming he continues serving the company. Each unit represents the right to receive one share of Emergent BioSolutions common stock, and Fowler now directly holds 5,006 shares following this grant.
Emergent BioSolutions Inc. director John D. Fowler Jr filed an initial ownership report on Form 3 showing he directly beneficially owns no shares of the company’s common stock as of the reported date. The filing does not report any buy or sell transactions, only a zero balance.
Emergent BioSolutions SVP, R&D, CMO Simon C. Lowry reported two equity compensation transactions. On March 5, 2026, 10,636 shares of common stock were disposed of at $8.44 per share to cover taxes tied to vesting and settlement of restricted stock units, leaving 77,803 shares held directly. On March 3, 2026, he received a grant of employee stock options for 44,834 shares at an exercise price of $0.00 per share, with the options vesting in three equal installments beginning the day before each anniversary of the grant date, increasing his directly held options to 147,833.